Search Results - Peter Lo
- Showing 1 - 3 results of 3
-
1
Delay of treatment change after objective progression on first‐line erlotinib in epidermal growth factor receptor‐mutant lung cancer by Peter Lo, Suzanne E. Dahlberg, Mizuki Nishino, Bruce E. Johnson, Lecia V. Sequist, David M. Jackman, Pasi A. Jänne, Geoffrey R. Oxnard
Published 2015Artigo -
2
-
3
Assigning clinical meaning to somatic and germ-line whole-exome sequencing data in a prospective cancer precision medicine study by Arezou A. Ghazani, Nelly Oliver, Joseph P. St. Pierre, Andrea Garofalo, Irene Rainville, Elaine Hiller, Daniel J. Treacy, Vanesa Rojas‐Rudilla, Sam Wood, Elizabeth F. Bair, Michael Parello, Franklin W. Huang, Marios Giannakis, Frederick H. Wilson, Elizabeth H. Stover, Steven M. Corsello, Tom Nguyen, Huma Q. Rana, Alanna J. Church, Carol Lowenstein, Carrie Cibulskis, Ali Amin‐Mansour, Jennifer Heng, Lauren K. Brais, Abigail Santos, Michael Bauer, Amanda Waldron, Peter Lo, Megan J. Gorman, Christine Lydon, Marisa W. Welch, Philip G. McNamara, Stacey Gabriel, Lynette M. Sholl, Neal I. Lindeman, Judy E. Garber, Steven Joffe, Eliezer M. Van Allen, Stacy W. Gray, Pasi A. Jänne, Levi A. Garraway, Nikhil Wagle
Published 2017Artigo
Search Tools:
Related Subjects
Cancer
Internal medicine
Medicine
Oncology
Biology
Colorectal cancer
Epidermal growth factor receptor
Gene
Genetics
Lung cancer
Adenocarcinoma
Bioinformatics
Cancer research
Chemotherapy
Clinical significance
Debulking
Environmental health
Erlotinib
Erlotinib Hydrochloride
Exome
Exome sequencing
Exon
Gefitinib
Genotype
Genotyping
Germline
KRAS
Mutation
Ovarian cancer
Pathology